Exome sequencing is a capture based method developed to identify variants in the coding region of genes which affect protein function. While exome capture methods using PCR, hybrid capture and molecular inversion probes exist, the most common and efficient strategies are in-solution capture methods. In-solution capture utilizes pools of oligonucleotides or probes bound to magnetic beads, whose sequence has been designed to hybridize to exon regions. After binding to genomic DNA, these probes are pulled down and washed, allowing exon regions to be selectively sequenced.
While there are approximately 180,000 exons in the human genome, constituting less than 2% of total sequence, the exome contains ~80-90% of known disease causing variants making it a cost-effective alternative to whole genome sequencing. When performing exome-seq, users should not only consider average on-target coverage but also the local coverage of particular sites of interest. When choosing between exome and whole genome sequencing (WGS), consider that exome sequencing has the advantage that oligonucleotides are designed to particular genomic regions where typical coverage with WGS is not enough for SNP calling. It is also more affordable enabling the analysis of more individuals and populations. With WGS, you can detect variants in regions not covered by exome capture allowing or the identification of structural and non-coding variants associated with disease.
This report contains market size and forecasts of Whole Exome Sequencing in Global, including the following market information:
Global Whole Exome Sequencing Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Whole Exome Sequencing market was valued at 304.6 million in 2021 and is projected to reach US$ 628.7 million by 2028, at a CAGR of 10.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Agilent HaloPlex Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Whole Exome Sequencing include Illumina, Thermo Fisher, Roche, Angilent, Eurofins, Sengenics, Ambry, Macrogen and BGI and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Whole Exome Sequencing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Whole Exome Sequencing Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Whole Exome Sequencing Market Segment Percentages, by Type, 2021 (%)
Agilent HaloPlex
Agilent SureSelect
Agilent SureSelect QXT
Illumina TruSeq Exome
Roche Nimblegen SeqCap
MYcroarray MYbaits
Global Whole Exome Sequencing Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Whole Exome Sequencing Market Segment Percentages, by Application, 2021 (%)
Correlation Research of Normal Human
Mendelian Disease and Rare Syndrome Gene Discovery
The Research of Complex Diseases
Mouse Exome Sequencing
Global Whole Exome Sequencing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Whole Exome Sequencing Market Segment Percentages, By Region and Country, 2021 (%)
North America
Nordic Countries
Rest of Europe
South Korea
Southeast Asia
Rest of Asia
South America
Rest of South America
Middle East & Africa
Saudi Arabia
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Whole Exome Sequencing revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Whole Exome Sequencing revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Thermo Fisher
Novo Gene


Please enter your comment!
Please enter your name here